Ellodi Pharmaceuticals is making significant strides in treating eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. EoE, often mistaken for GERD, leads to severe symptoms like pain, difficulty swallowing, and even food impaction, affecting quality of life for many patients. The condition typically requires systemic corticosteroids for symptom management, but these treatments come with serious side effects, particularly for long-term use.

To address this, Ellodi Pharmaceuticals has developed a novel approach: a low-dose, orally administered corticosteroid that works topically, targeting the esophagus directly without heavy systemic absorption. This innovation minimizes the usual risks of long-term corticosteroid use, such as immune suppression and adrenal issues, while effectively reducing esophageal inflammation. The treatment protocol is designed in two phases: an induction phase to quickly reduce inflammation, followed by a maintenance phase to keep symptoms under control.

One of the most distinctive aspects of Ellodi’s approach is the way the drug is administered. Patients take the medication while lying down, allowing for more direct contact with the esophageal lining, enhancing its topical effects. Early data show promising outcomes, including significant reductions in eosinophil counts—a primary marker of EoE inflammation—improved esophageal structure and function, and more dysphagia-free days.

Ellodi’s therapy marks a shift towards safer, more targeted EoE treatments, offering a new option for patients who struggle with the limitations of current systemic therapies. By focusing on a topical solution, Ellodi Pharmaceuticals is paving the way for improved, patient-friendly treatment options for gastrointestinal inflammatory conditions like EoE.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/